TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

176 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • DepressionAnxiety

    Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease

    Testing whether therapy sessions can help teens and young adults with sickle cell cope with

    📍 Children's Hospital Los Angeles · Los Angeles, CA · Get directions →

    The current study seeks to build on previous research that demonstrates the efficacy of Acceptance and Commitment Therapy in combating stigma by investigating the feasibility and acceptability of a protocol to support Black adolescents and young adults in coping with race related stress. The study will consist of a small, purposeful, non-randomized sample (N = 30) of clients enrolled into a 10-session Acceptance and Commitment Therapy group.

    ✓ Study care freePhase 1Ages 14–21Learn more →
  • Dementia / Alzheimer'sParkinson's disease

    Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments

    Testing whether a tributyrin supplement helps memory, thinking, and balance in adults with Parkinson

    📍 Domino's Farms · Ann Arbor, MI · Get directions →

    The goal of this clinical trial is to learn if taking a tributyrin supplement works to improve memory and thinking and walking and balance in adults with Parkinson disease Parkinson disease dementia. It will also learn about the safety of tributyrin supplementation.

    ✓ Study care freePhase 1Ages 45+Learn more →
  • Parkinson's disease

    Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms

    Testing a non-invasive brain stimulation device to improve Parkinson’s movement problems

    📍 U LLC Headquarters · Cleveland, OH · Get directions →

    This study tests a new, non-invasive brain stimulation device called Sphere V3.0 to help improve movement problems in people with Parkinson's disease. The device delivers gentle electrical signals to the scalp using small electrodes placed on the head.

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • Sickle cell disease

    A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

    Testing different doses of DISC-3405 to check safety in sickle cell disease

    📍 University of Alabama at Birmingham · Birmingham, AL · +6 more US sites · Get directions →

    This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405 and will assess the safety, tolerability, PK, and PD of DISC 3405 in participants with sickle cell disease.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Parkinson's disease

    First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)

    Testing an experimental treatment for early Parkinson’s disease in adults

    📍 Montreal Neurological Institute and Hospital · Montreal, Quebec · Get directions →

    This study is researching an experimental drug called ALN-SNCA (called "study drug"). The study is focused on people with early Parkinson's disease, a disorder of the nervous system that affects movement.

    ✓ Study care freePhase 1Ages 50–80Learn more →
  • DepressionAnxiety

    Personalized Brain Stimulation to Treat Chronic Concussive Symptoms

    Testing personalized brain stimulation for ongoing concussion symptoms

    📍 UCLA · Westwood, Los Angeles, CA · Get directions →

    The goal of this study is to investigate a new treatment for chronic symptoms after concussion or mild traumatic brain injury in people aged 18-65 years old. Chronic symptoms could include dizziness, headache, fatigue, brain fog, memory difficulty, sleep disruption, irritability, or anxiety that occurred or worsened after the injury.

    ✓ Study care freePhase 2Ages 18–65Learn more →
  • Parkinson's disease

    Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis

    Testing whether a low-dose seizure medicine can help Parkinson’s psychosis

    📍 Johns Hopkins · Baltimore, MD · Get directions →

    This clinical trial will test whether AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) can improve symptoms of psychosis in Parkinson's disease. Participants will be asked to complete up to 5 in-person study visits over approximately 20 weeks.

    ✓ Study care freePhase 2Ages 40–85Learn more →
  • Anxiety

    Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder

    Testing a single oral dose medicine versus placebo for social anxiety in adults

    📍 Vanda Investigational Site · Phoenix, AZ · +30 more US sites · Get directions →

    This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in adults with social anxiety disorder.

    ✓ Study care freePhase 3Ages 18–65Learn more →
  • Parkinson's disease

    A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

    Testing a treatment in people with early Parkinson’s disease who have an LRRK2 gene test result

    📍 Banner Sun Health Research Institute · Sun City, AZ · +39 more US sites · Get directions →

    The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Parkinson's disease

    📍 University of Kentucky · Lexington, KY · Get directions →

    The investigators propose a Phase I single surgical-center, double-blinded randomized parallel clinical trial involving bilateral autologous peripheral nerve tissue (PNT) delivery into the NBM or the alternate target also affecting cognition in this population, the substantia nigra (SN), to address "repair cell" support of these areas. Twenty-four participants with idiopathic Parkinson's Disease (PD) who have selected, qualified and agreed to receive as standard of care deep brain stimulation (DBS) will be enrolled and randomly allocated to receive bilateral PNT deployment to either the NBM or SN at the time of DBS surgery.

    ✓ Study care freePhase 1Ages 45–75Learn more →
  • Anxiety

    Self-Adjusted Nitrous Oxide: A Feasibility Study in the Setting of Vasectomy

    Testing whether self-controlled nitrous oxide during vasectomy lowers pain and anxiety

    📍 Beth Israel Deaconess Medical Center · Boston, MA · Get directions →

    This study is being done to see if nitrous oxide during vasectomy decreases pain and anxiety, and also assess whether patients have better satisfaction when they control their own level of nitrous oxide during the procedure. If we find that patients experience less pain or anxiety with nitrous oxide, it could be suggested that self-adjusted nitrous oxide (SANO) may be a useful tool for improving experience of care during vasectomy.

    ✓ Study care freePhase 4Ages 21–85MenLearn more →
  • DepressionAnxiety

    ACT for Individuals With MNCD and Their Care Partners

    Testing acceptance commitment therapy for depression and anxiety in dementia

    📍 Texas Tech University Plaza Building · Lubbock, TX · Get directions →

    This project aims to implement and evaluate a dyadic intervention (i.e., acceptance commitment therapy) for persons with AD/ADRD and their care partners. We hypothesize the intervention will be feasible, acceptable, and show preliminary efficacy of the dyadic interveniotns.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Sickle cell disease

    Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease

    Testing higher doses of VAS-101 in people with stable sickle cell disease

    💵 May compensate

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: Sickle cell disease (SCD) is an inherited blood disorder. The disease affects the ability of red blood cells to carry oxygen.

    ✓ Study care freePhase 1Ages 18–90Learn more →
  • Parkinson's disease

    A Study of Buntanetap in Participants With PD

    Testing the long-term safety of buntanetap in people with Parkinson’s

    📍 University of Alabama at Birmingham · Birmingham, AL · +26 more US sites · Get directions →

    This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study.

    ✓ Study care freePhase 2Ages 40–85Learn more →
  • DepressionAnxiety

    iTBS+D-Cycloserine for Youth Suicide

    Testing a treatment for depression and anxiety to reduce youth suicide risk

    📍 University of Calgary · Calgary, Alberta · Get directions →

    Background and Rationale: Suicide is the second leading cause of death in Canadian Emerging Adults (EAs; 18-24yrs). Current treatments for suicidal thoughts and behaviors are limited and novel treatments are required to save lives.

    ✓ Study care freePhase 2Ages 18–24Learn more →
  • Dementia / Alzheimer'sParkinson's disease

    PET Imaging Evaluation of [11C]SY08

    Testing a PET scan tracer to detect alpha-synuclein protein clumps in dementia and Parkinson’s

    📍 MGH · Charlestown, MA · Get directions →

    The overall goal of the proposed research is to evaluate the use of \[11C\]SY08 as a PET radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD), Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls. The purpose of this study is to evaluate the use of \[11C\]SY08 as a PET radiotracer for αS fibrils in individuals with PD, MSA, DLB and healthy controls.

    ✓ Study care freeEarly Phase 1Ages 50–80Learn more →
  • Sickle cell disease

    A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)

    Testing the safety and how an oral carbon monoxide liquid works in sickle cell disease

    📍 Cevaxin - The Panama Clinic · Panama City, · Get directions →

    This is a multi-center, open label Phase 2a clinical trial in subjects with sickle cell disease to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of HBI-002, an orally administered liquid containing carbon monoxide (CO), with doses daily for 14 days.

    ✓ Study care freePhase 1Ages 18–55Learn more →
  • DepressionAnxiety

    Perinatal Depression & Anxiety (PDA) and Maternal Gut Microbiome

    Studying how gut bacteria in pregnant people relates to depression and anxiety

    📍 Sunnybrook Health Science Center · Toronto, Ontario · Get directions →

    Perinatal depression and anxiety (PDA) are the leading causes of maternal mortality in developed countries. Women with a history of depression have a 20 fold higher risk of PDA at subsequent pregnancies.

    ✓ Study care freePhase 2Ages 18–43WomenLearn more →
  • Sickle cell disease

    Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults

    Testing whether a low dose of ketamine helps treat sickle cell pain in children and young adults

    📍 Harbor UCLA Medical Center · Torrance, CA · Get directions →

    The purpose of this research is to see if ketamine is effective and safe in treating children and young adults with sickle cell disease experiencing sickle cell related pain. In this study, we will compare the outcomes (such as pain scores) in persons who receive standard of care pain medicine (an opioid such as morphine) plus a low dose (amount) of ketamine to those who receive only standard of care pain medicine.

    ✓ Study care freePhase 2Ages 5–20Learn more →
  • Anxiety

    Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders

    Testing whether sertraline works better than a placebo for anxiety in children with

    📍 Alberta Children's Hospital - University of Calgary · Calgary, Alberta · Get directions →

    There are currently no approved medications for the treatment of anxiety in children and youth with neurodevelopmental disorders (NDDs), both common and rare. Sertraline, a selective serotonin reuptake inhibitor, has extensive evidence to support its use in children's and youth with anxiety but not within NDDs.

    ✓ Study care freePhase 2Ages 8–17Learn more →
  • Parkinson's disease

    Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies

    Testing an injection for brain scans to study Parkinson’s disease and safety

    📍 Institute for Neurodegenerative Disorders and XingImaging, LLC · New Haven, CT · Get directions →

    This is a single-center, open-label clinical study designed to evaluate the imaging characteristics and safety of \[¹⁸F\]MODAG-009 in participants with Parkinson's disease (PD), Multiple system atrophy (MSA), and Healthy controls (HC). Approximately 13 participants will be enrolled in this study.

    ✓ Study care freeEarly Phase 1Ages 50–80Learn more →
  • DepressionAnxiety

    Nebulized Ketamine for the Treatment of Major Depressive Disorder

    Testing a breathing mist of ketamine to reduce symptoms of major depression

    📍 Maimonides Medical Center · Brooklyn, NY · Get directions →

    This is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.

    ✓ Study care freePhase 3Ages 18–88Learn more →
  • Parkinson's disease

    A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

    Testing a Parkinson’s surgery approach to see if it is safe and works

    📍 Banner Sun Health Research Institute · Sun City, AZ · +32 more US sites · Get directions →

    Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).

    ✓ Study care freePhase 3Ages 45–75Learn more →
  • Parkinson's disease

    A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

    Testing a carbidopa and levodopa extended-release capsule in people with Parkinson’s

    📍 Barrow Neurological Institute · Phoenix, AZ · +26 more US sites · Get directions →

    The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).

    ✓ Study care freePhase 4Ages 18+Learn more →
  • DepressionAnxiety

    Leveraging mHealth to Promote Opioid Use Recovery and Mental Health Among Residents of a Medium-Sized Midwestern City

    Testing whether a phone-based program supports opioid recovery and mental health

    📍 Washington University School of Medicine · St Louis, MO · Get directions →

    The sequential trial compares recovery and mHealth engagement outcomes among Black participants who participated in the mHealth intervention uMAT-R or uMAT-R + enhanced community engagement. The mHealth intervention seeks to support people in various stages of recovery who are also seeking other forms of substance use treatment.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Sickle cell disease

    The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

    Testing rilzabrutinib for safety and effectiveness in sickle-cell disease

    📍 University of Alabama at Birmingham- Site Number : 8400003 · Birmingham, AL · +15 more US sites · Get directions →

    This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-adaptive, group-sequential study (Part A), followed by an open-label LTE period (Part B) to investigate the efficacy, and safety of rilzabrutinib in participants with sickle-cell disease (SCD). Study details include: * Study duration: a 52-week double-blind period (Part A), followed by an open-label LTE period (Part B).

    ✓ Study care freePhase 3Ages 10–65Learn more →
  • DepressionAnxiety

    Integrating Inuit Knowledge Principles in Multi-Level Mental Health Clinical Trials

    Testing whether eating more country foods and cultural activities help Inuit adults with depression

    📍 Aqqiumavvik Society · Arviat, Nunavut · Get directions →

    This study is looking at how eating more country foods affects mental health among Inuit men and women in Arviat, NU. The goal is to evaluate if eating more of these foods helps people feel less depressed or anxious, and whether being part of food-gathering and cultural activities also makes a difference.

    ✓ Study care freeEarly Phase 1Ages 18–65Learn more →
  • Anxiety

    Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

    Testing whether adding ABBV-932 to antidepressants is safe and helps adults with generalized anxiety

    📍 University of Alabama - Huntsville Regional Medical Campus /ID# 267818 · Huntsville, AL · +39 more US sites · Get directions →

    Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs.

    ✓ Study care freePhase 2Ages 18–65Learn more →
  • Sickle cell disease

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

    Testing whether extra arginine lowers pain in children with sickle cell

    📍 Children's Healthcare fo Atlanta at Hughes Spalding · Atlanta, GA · +1 more US site · Get directions →

    The purpose of this study is to determine whether giving extra arginine to patients with sickle cell disease seeking treatment for vaso-occlusive painful events (VOE) will decrease pain scores, decrease need for pain medications or decrease length of hospital stay or emergency department visit.

    ✓ Study care freePhase 1Ages 7–21Learn more →
  • DepressionAnxiety

    Creatine for Depressed Male and Female Methamphetamine Users

    Testing whether creatine helps depression and anxiety in people who use meth

    📍 Montana State University College of Nursing (Missoula campus) · Missoula, MT · Get directions →

    * Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users * Assess creatine's effect on methamphetamine use * Assess the safety of creatine in male methamphetamine users with depression

    ✓ Study care freePhase 3Ages 18–59Learn more →
  • Sickle cell disease

    A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease

    Testing a once-daily mouth medicine in teens with sickle cell disease

    📍 The Hospital for Sick Children · Toronto, Ontario · Get directions →

    This study is being done to learn about etavopivat, a once a day medicine taken by mouth in adolescents with sickle cell disease. The main goals are to study safety and how long etavopivat stays in the bloodstream, while also studying if there are benefits from taking etavopivat.

    ✓ Study care freePhase 2Ages 1–18Learn more →
  • Parkinson's disease

    Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease

    Testing a new PET brain scan to measure nerve protein buildup in Parkinson’s

    📍 Invicro (dba Perceptive) · New Haven, CT · +1 more US site · Get directions →

    This clinical study is being conducted to learn more about a new imaging drug called \[18F\]MK-0947, which is designed to help doctors see changes in the brain related to Parkinson's disease (PD). PD is a condition that affects movement, balance, and thinking.

    ✓ Study care freeEarly Phase 1Ages 18–80Learn more →
  • DepressionAnxiety

    A New Intervention to Improve Function in Veterans With Anxiety and Depression

    Testing a new treatment to improve daily functioning in veterans with anxiety and depression

    📍 Durham VA Medical Center, Durham, NC · Durham, NC · Get directions →

    Anxiety and depression symptoms occur at high rates in Veteran populations and can significantly impact function, compromising the ability to work and to successfully form and maintain valued relationships. Several other symptoms commonly occur with anxiety and depression, including poor sleep quality and chronic pain.

    ✓ Study care freePhase 2Ages 18–65Learn more →
  • Sickle cell disease

    RH Genotype Matched RBC Transfusions

    Testing whether matching donor red blood cells by RH type helps people with sickle cell who need

    📍 Children's Hospital of Philadelphia · Philadelphia, PA · Get directions →

    To determine the feasibility and efficacy of matching donor red cells by RH genotype for a cohort of chronically transfused patients with SCD.

    ✓ Study care freePhase 1Ages 1+Learn more →
  • Anxiety

    Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)

    Testing whether genetic-guided dosing of a daily anxiety medicine helps kids

    📍 University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience · Cincinnati, OH · Get directions →

    This double-blind, 12-week study will consist include132 anxious youth who are randomized (1:1) to standard or pharmacogenetically-guided escitalopram dosing. Block randomization (1:1) will be stratified by sex and metabolizer status.

    ✓ Study care freePhase 4Ages 12–17Learn more →
  • DepressionParkinson's disease

    Imaging Depression in Parkinson's Disease

    Studying brain changes linked to depression in people with Parkinson’s

    📍 Yale University · New Haven, CT · Get directions →

    The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Parkinson's disease

    A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

    Testing an IV medicine in healthy people and people with Parkinson’s

    📍 Collaborative Neuroscience Network - CNS · Los Alamitos, CA · +11 more US sites · Get directions →

    The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.

    ✓ Study care freePhase 1Ages 30–85Learn more →
  • Anxiety

    Adjunctive Treatment With L-methylfolate for Treatment-Resistant Generalized Anxiety Disorder: a Pilot Study

    Testing whether adding L-methylfolate is safe and tolerated for hard-to-treat anxiety

    📍 Kingston Health Sciences Centre · Kingston, Ontario · Get directions →

    The goal of this feasibility study is to determine the tolerability and safety of add on treatment with L-methylfolate in patients with treatment-resistant generalized anxiety disorder (GAD). The primary objective is to monitor for side effects and other risks associated with the treatment.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Anxiety

    📍 Servicios Especializados En Ensayos Clinicos, Seec, Sc · Mexico City, Mexico City · Get directions →

    To evaluate the superiority of cognitive behavioral therapy using the Aurora® digital medical device + conventional drug treatment, compared to conventional drug treatment alone, in reducing anxiety symptoms, as assessed by the change in the GAD-7 scale at 12 weeks of treatment, relative to baseline.

    ✓ Study care freePhase 3Ages 18–65Learn more →
  • Parkinson's disease

    Ketamine for Veterans With Parkinson's Disease

    Testing ketamine for depression in veterans with Parkinson’s disease

    📍 San Francisco VA Medical Center, San Francisco, CA · San Francisco, CA · Get directions →

    Parkinson's disease (PD) is a devastating illness that has a growing impact on Veterans. One of the most disabling symptoms is depression, which is common in PD and linked to poor quality of life and higher risk of suicide.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • DepressionAnxiety

    Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

    Testing psilocybin-assisted therapy for depression and anxiety in people with advanced cancer

    💵 May compensate

    📍 MD Anderson Cancer Center · Houston, TX · Get directions →

    To learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy on depression and/or anxiety in participants who are being treated for advanced cancer.

    ✓ Study care freePhase 2Ages 25+Learn more →
  • Parkinson's disease

    SAD Study in Patients With Parkinson's Disease and Motor Fluctuations

    Testing a single dose of SER-252 in people with Parkinson’s disease

    💵 May compensate

    📍 Rocky Mountain Clinical Research · Englewood, CO · +3 more US sites · Get directions →

    This is a randomized, placebo-controlled, single ascending dose (SAD) study of SER-252 in participants with Parkinson's Disease (PD) and motor fluctuations.

    ✓ Study care freePhase 1Ages 40–80Learn more →
  • Sickle cell disease

    Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease

    Testing a one-time blood stem cell transplant using gene editing for severe sickle cell disease

    📍 University of California, Los Angeles · Los Angeles, CA · +1 more US site · Get directions →

    This is an open label, non-randomized, 2-center, phase 1/2 trial of a single infusion of sickle allele modified cluster of differentiation (CD34+) hematopoietic stem progenitor cells (HSPCs) in subjects with in subjects ≥12 years old to 35 years old severe Sickle Cell Disease (SCD). The study will evaluate the hematopoietic stem cell transplantation (HSCT) using CRISPR/Cas9 edited red blood cells (known as CRISPR\_SCD001 Drug Product).

    ✓ Study care freePhase 1Ages 12–35Learn more →
  • Parkinson's disease

    18F-DOPA II - PET Imaging Optimization

    Testing an imaging scan to study Parkinson’s disease using PET

    📍 WC Mackenzie Health Science Centre / University of Alberta Hospital · Edmonton, Alberta · Get directions →

    A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: 1. Pediatric patients (less than 18 years old) with congenital hyperinsulinism.

    ✓ Study care freePhase 3Learn more →
  • DepressionAnxiety

    TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

    Testing psilocybin-assisted therapy for depression and anxiety in cancer survivors

    💵 May compensate

    📍 The University of Texas M. D. Anderson Cancer Center · Houston, TX · Get directions →

    This clinical research study is to learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy for cancer survivors with depression and/or anxiety.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Anxiety

    RE104 Safety and Efficacy Study in Generalized Anxiety Disorder

    Testing whether a single dose injection reduces anxiety symptoms

    📍 Lighthouse Psychiatry · Gilbert, AZ · +21 more US sites · Get directions →

    The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.

    ✓ Study care freePhase 2Ages 18–74Learn more →
  • Parkinson's disease

    Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)

    Tracking how brain scans change over time in people with early Parkinson’s

    📍 Institute for Neurodegenerative Disorders · New Haven, CT · +1 more US site · Get directions →

    The study is a longitudinal, multi-center study to assess progression of \[18F\] AV-133 imaging in Prodromal PD participants. Participants will be followed for up to 24 months.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • DepressionAnxiety

    Open-Label Psilocybin Study in Transdiagnostic Population

    Testing psilocybin for safety and symptom changes in people with depression or anxiety

    📍 Connecticut Mental Health Center - Yale School of Medicine · New Haven, CT · Get directions →

    The primary objective of this study is to investigate the safety, feasibility, and tolerability of psilocybin treatment in individuals with functional impairment due to psychiatric symptoms. The secondary objective of this study is to determine whether individuals with functional impairments due to psychiatric symptoms will experience statistically significant symptom reduction and functional improvement from baseline symptom measurements (Visit 3) to 1-week (Visit 7), 4-weeks (Visit 8), and 6-weeks (Visit 9) post dosing.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • DepressionParkinson's disease

    Psilocybin Therapy for Depression in Parkinson's Disease

    Testing whether psilocybin therapy improves depression symptoms in people with Parkinson’s disease

    📍 University of California, San Francisco · San Francisco, CA · Get directions →

    The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • DepressionAnxiety

    Use of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use

    Testing a chatbot to support people using cannabis with anxiety or depression

    📍 46 Centerra Parkway, Suite 300, Office #333S · Lebanon, NH · Get directions →

    This study tests a chatbot called Therabot-CALM to help people who use cannabis with anxiety and/or low mood. Participants will do questionnaires, try the chatbot for 4 weeks, and join virtual interviews to give feedback on how usable and helpful it feels. The goal is to see if the chatbot is acceptable to users and can improve symptoms.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • DepressionAnxiety

    Psilocybin-Assisted Therapy for Intergenerational Trauma

    Testing psilocybin-assisted therapy for depression and anxiety in children of genocide survivors

    📍 The Parsons Research Center for Psychedelic Healing · New York, NY · Get directions →

    This is an open-label psilocybin-assisted therapy study that will examine the safety and tolerability of psilocybin-assisted therapy in the offspring of genocide survivors with mood and anxiety disorders. The study will also investigate the efficacy of psilocybin-assisted therapy in reducing symptoms such as depression, anxiety and stress, as well as changes to the psychological effects of parental exposure to genocide, and changes to psychological resilience.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Anxiety

    The Impact of Focused Ultrasound Thalamotomy of the Anterior Nucleus for Focal-Onset Epilepsy on Anxiety

    Testing whether focused ultrasound thalamotomy can improve anxiety

    📍 The Ohio State University · Columbus, OH · Get directions →

    The purpose of this study is to evaluate the feasibility, safety, and effects on anxiety of high intensity focused ultrasound ablation (FUSA) in patients suffering from treatment-refractory focal epilepsy and anxiety. FUSA is a non-invasive neurosurgical procedure that uses ultrasound waves, sent directly through the scalp and skull, to precisely target small abnormal areas of the brain.

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Sickle cell disease

    Cannabidiol in Sickle Cell Disease

    Testing twice-daily cannabidiol doses for people with sickle cell disease

    📍 Icahn School of Medicine at Mount Sinai · Manhattan, NY · Get directions →

    Randomized, placebo-controlled, double masked, dose finding study of twice daily cannabidiol given at 3 dose levels, 200mg, 400mg, and 600mg, compared to placebo for 4 weeks.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Parkinson's disease

    Cortical Electrophysiology of Response Inhibition in Parkinson's Disease

    Studying how deep brain stimulation in Parkinson’s affects brain control of stopping actions

    📍 Emory University Hospital · Atlanta, GA · +1 more US site · Get directions →

    Patients with Parkinson's Disease will be studied before, during, and after a deep brain stimulation implantation procedure to see if the stimulation location and the size of the electrical field produced by subthalamic nucleus (STN) DBS determine the degree to which DBS engages circuits that involve prefrontal cortex executive functions, and therefore have a direct impact on the patient's ability to inhibit actions.

    ✓ Study care freePhase 4Ages 45–75Learn more →
  • Parkinson's disease

    Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Exosomes for Parkinson's Disease

    Testing the safety and effectiveness of nose drops made from donor stem cell exosomes for

    📍 Medical Surgical Associates Center · St John's, · Get directions →

    This trial will study the safety and efficacy of intranasal instillation of cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosomes for the treatment of Parkinson's Disease

    ✓ Study care freePhase 1Learn more →
  • Sickle cell disease

    Early Screening and Treatment of Heart Complication in Sickle Cell Disease

    Testing early heart screening and iron overload treatment in people with sickle cell disease

    📍 Inova Schar Cancer · Fairfax, VA · +1 more US site · Get directions →

    This study tests whether early heart screening and treatment for iron overload in subjects with sickle cell disease can prevent heart problems and reduce hospitalizations.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Sickle cell disease

    Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease

    Testing whether routine red blood cell transfusions in pregnancy reduce sickle cell flare-ups or

    📍 Grady Health System · Atlanta, GA · Get directions →

    The goal of this study is to determine if there is a positive effect of prophylactic red blood cell (RBC) transfusion of leukoreduced, ABO, Rh (D/Cc/Ee) and Kell matched blood compared to standard of care on the number of episodes of acute sickle cell disease (SCD) manifestations or pregnancy-related complications requiring acute health care encounters (acute care/ER/Hospital visits) or resulting in death over the entirety of pregnancy until 2 months post-partum in women with SCD. RBC transfusion is the only disease-modifying therapy for pregnant women with SCD, and it is considered a standard treatment option however, there exists no consensus on the role of transfusion therapy in preventing SCD-related pregnancy complications.

    ✓ Study care freePhase 4Ages 18+WomenLearn more →
  • Sickle cell disease

    Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial

    Testing two daily doses of zinc in people with sickle cell disease to see changes in bone-related

    📍 UCSF Benioff Children's Hospital Oakland · Oakland, CA · +5 more US sites · Get directions →

    The goal of this short term prospective Phase II study is to compare the effects of two alternate daily doses of zinc (25 and 40 mg/day) in 34 randomly assigned homozygous Sickle Cell Disease (SCD-SS) patients aged 15-40 years old. The main question it aims to answer is: Which biomarkers are most responsive to zinc supplementation, and what is the maximum tolerated zinc dose that induces the desired changes in biomarkers of bone turnover?

    ✓ Study care freePhase 2Ages 15–40Learn more →
  • Sickle cell disease

    Gene Editing For Sickle Cell Disease

    Testing whether gene editing is safe for people with sickle cell disease

    📍 St. Jude Children's Research Hospital · Memphis, TN · Get directions →

    This study is being done to test the safety of a new treatment called gene editing in Sickle Cell Disease (SCD) patients and to see if a single dose of this genetically modified cellular product will increase the amount of a certain hemoglobin called fetal hemoglobin (HbF) and help reduce the symptoms of SCD. Primary Objective * To assess the safety of autologous infusion of clustered regularly interspaced palindromic repeats (CRISPR)/ CRISPR associated protein (Cas9)-edited CD34+ hematopoietic stem and progenitor cells (HSPCs) in patients with severe SCD.

    ✓ Study care freePhase 1Ages 18–24Learn more →
  • Sickle cell disease

    Allo HSCT for High Risk Hemoglobinopathies

    Testing donor stem cell transplant for people with high-risk sickle cell

    📍 Masonic Cancer Center · Minneapolis, MN · Get directions →

    A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.

    ✓ Study care freePhase 2Learn more →
  • Showing the first 60 of 176. Add filters or a location to narrow down.